Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer

NCT04555837 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma
Malignant Solid Neoplasm

Interventions

DRUG: Alisertib
BIOLOGICAL: Pembrolizumab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]